Recently, it was hypothesized, that TET2, which is frequently mutated in hematologic malignancies, maintains genomic stability via promotion of DNA damage repair and that loss of TET2 might sensitize myeloid leukemia cells to PARP inhibitors (102). This evidence concerns the gene TET2 and myeloid leukemia.